04/23/2026
DMARDs and biologics aren’t always “forever” but stopping them isn’t as simple as feeling better.
In rheumatology, we use a treat-to-target approach: control inflammation early, aim for remission (or low disease activity), and then reassess. In patients with sustained remission, guidelines (like ACR/EULAR) support careful tapering not abrupt stopping.
What does the data show?
* Tapering can be successful in a subset of patients, especially with deep, stable remission.
* Flare risk increases as you reduce or stop therapy. This is the trade-off.
* Most patients who flare can regain control when treatment is restarted, but not always immediately.
So this becomes less of a protocol…and more of an art:
Sometimes tapering works beautifully.
Sometimes it doesn’t and that’s okay. We adjust, regain control, and reassess again.
The goal isn’t just to stop meds.
It’s to protect joints, prevent damage, and maintain quality of life long term.